Teijin Limited

Teijin Pharma Limited

Km Biologics Co., Ltd.

The Chemo-sero-therapeutic Research Institute

Kentaro Fujinaga

Susumu Honda

Hiroaki Kaneko

Makoto Satake

Yukako Kageyama

Ayuko Yamaguchi

Takayuki Imamura

Masaki Hirashima

Ryoichi Kawamura

Yusuke Akiyama

Akitoshi Oono

Yoshiaki Igarashi

Susumu Maruo

Yoji Yamamoto

Hirofumi Tanabe

Kiyoyuki Sakon

Tsutomu Mochizuki

Hiroaki Mitsuhashi

Michiharu Kageyama

Masahiko Narasaki

Kazuoki Tsuruta

Ayumi Ishiwari

Hideaki Nakamura

Kenji Sunagawa

Yukiko Kimura

Souichirou Katou

A formed sheet product of a polymer composition comprising at least one protein selected from the group consisting of fibrinogen and thrombin and at least one polymer selected from the group consisting of an aliphatic polyester and a water-soluble polymer, and a laminated formed sheet product comprising a first polymer composition layer composed of fibrinogen and a water-soluble polymer and a second polymer composition layer composed of thrombin and an aliphatic polyester are provided. These formed products are applied onto a wound site and function as a hemostatic material.

Formed sheet product and hemostatic material

A sterile composition which comprises a protein and an aliphatic polyester containing the protein and is sterilized with radiation. In this sterile composition, the structure and function (activity) of the protein are retained.

Sterile composition

Disclosed is a controlled release nucleated tablet which is composed of an inner nucleus and an outer layer that covers the inner nucleus and is capable of maintaining the level of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid in the blood to a certain value or higher for a long period of time. The controlled release nucleated tablet is characterized in that the inner nucleus contains 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and the outer layer contains 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and a gel-forming water-soluble polymer that is in an amount of 16 (w/w) % or more relative to the weight of the outer layer.

Controlled release coat-core tablet

A medicinal composition containing one or more compounds selected from the compounds represented by the following formula (I), salts of these compounds, solvates of these compounds and solvates of these salts and being capable of reducing the contact of the compounds with the components in the bile or pancreatic juice.

Release-regulating preparations comprising biphenyldiamine derivatives

Growing community of inventors

Hino, Japan

Kentaro Fujinaga